Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 262

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study

Open access
Villa, Erica, Critelli, Rosina, Lei, Barbara, Marzocchi, Guido, Cammà, Calogero, Giannelli, Gianluigi, Pontisso, Patrizia, Cabibbo, Giuseppe, Enea, Marco, Colopi, Stefano, Caporali, Cristian, Pollicino, Teresa, Milosa, Fabiola, Karampatou, Aimilia, Todesca, Paola, Bertolini, Elena, Maccio, Livia, Martinez-Chantar, Maria Luz, Turola, Elena, Del Buono, Mariagrazia, De Maria, Nicola, Ballestri, Stefano, Schepis, Filippo, Loria, Paola, Enrico Gerunda, Giorgio, Losi, Luisa, Cillo, Umberto·2016·Gut

Abstract

Objective: The biological heterogeneity of hepatocellular carcinoma (HCC) makes prognosis difficult. We translate the results of a genome-wide high-throughput analysis into a tool that accurately predicts at presentation tumour growth and survival of patients with HCC. Design: Ultrasound surveillance identified HCC in 78 (training set) and 54 (validation set) consecutive patients with cirrhosis. Patients underwent two CT scans 6 weeks apart (no treatment in-between) to determine tumour volumes (V 0 and V 1) and calculate HCC doubling time. Baseline-paired HCC and surrounding tissue biopsies for microarray study (Agilent Whole Human Genome Oligo Microarrays) were also obtained. Predictors of survival were assessed by multivariate Cox model. Results: Calculated tumour doubling times ranged from 30 to 621 days (mean, 107±91 days; median, 83 days) and were divided into quartiles: ≤53 days (n=19), 54–82 days (n=20), 83–110 days (n=20) and ≥111 days (n=19). Median survival according to doubling time was significantly lower for the first quartile versus the others (11 vs 41 months, 42, and 47 months, respectively) (p<0.0001). A five-gene transcriptomic hepatic signature including angiopoietin-2 (ANGPT2), delta-like ligand 4 (DLL4), neuropilin (NRP)/tolloid (TLL)-like 2 (NETO2), endothelial cell-specific molecule-1 (ESM1), and nuclear receptor subfamily 4, group A, member 1 (NR4A1) was found to accurately identify rapidly growing HCCs of the first quartile (ROC AUC: 0.961; 95% CI 0.919 to 1.000; p<0.0001) and to be an independent factor for mortality (HR: 3.987; 95% CI 1.941 to 8.193, p<0.0001). Conclusions: The hepatic five-gene signature was able to predict HCC growth in individual patient and the consequent risk of death. This implies a role of this molecular tool in the future therapeutic management of patients with HCC. Trial registration number: ClinicalTrials.gov Identifier: NCT01657695.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2014-308483

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 262

Metadata

Authors
Villa, E., Critelli, R., Lei, B., Marzocchi, G., Cammà, C., Giannelli, G., Pontisso, P., Cabibbo, G., Enea, M., Colopi, S., Caporali, C., Pollicino, T., Milosa, F., Karampatou, A., Todesca, P., Bertolini, E., Maccio, L., Martinez-Chantar, M. L., Turola, E., Del Buono, M., De Maria, N., Ballestri, S., Schepis, F., Loria, P., Enrico Gerunda, G., Losi, L., & Cillo, U.
Venue
Gut
Publisher
BMJ
Published
2015-02-09
Volume
65
Issue
5
Pages
861-869
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2127712585
Cited by
262
References
37
FWCI
10.40
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. https://app.cochat.ai/papers/10.1136/gutjnl-2014-308483
The paper
Villa, E., Critelli, R., Lei, B., Marzocchi, G., Cammà, C., Giannelli, G., Pontisso, P., Cabibbo, G., Enea, M., Colopi, S., Caporali, C., Pollicino, T., Milosa, F., Karampatou, A., Todesca, P., Bertolini, E., Maccio, L., Martinez-Chantar, M. L., Turola, E., . . . Cillo, U. (2016). Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. Gut. https://doi.org/10.1136/gutjnl-2014-308483

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.